Cabazitaxel
Cabazitaxel is a chemotherapy medication used in the treatment of advanced prostate cancer.Cabazitaxel is a microtubule inhibitor that belongs to the taxane class of chemotherapeutic agents. It works by disrupting microtubule dynamics, thereby inhibiting cell division and causing cell death.-Cabazitaxel is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received docetaxel-based chemotherapy. -Cabazitaxel is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.
-The recommended dosage of Cabazitaxel is typically administered intravenously at a dose of 25 mg/m² every three weeks. The dosage may be adjusted based on individual patient characteristics and tolerability. -IV; Dosage is based on calculation of the Body Surface Area (BSA), and is 20 mg/m2 administered as a one-hour intravenous infusion every three weeks in combination with oral prednisone 10 mg administered daily throughout JEVTANA treatment. Dose modification is required in toxicity or liver impairment .
-Cabazitaxel is contraindicated in patients with a history of severe hypersensitivity reactions to cabazitaxel or other drugs formulated with polysorbate 80. -Neutrophil counts of d” 1,500/mm³, history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate , severe hepatic impairment (total bilirubin >3 × ULN)
-Patients should be premedicated with appropriate medications to minimize the risk of hypersensitivity reactions. -Blood cell counts should be monitored regularly, and dose adjustments may be necessary in case of myelosuppression. -Patients with hepatic impairment may require dose adjustments. Use with caution in hepatic impairment Paediatric: The safety and effectiveness in pediatric patients have not been established. Pregnancy: N.A. Lactation: N.A. Elderly: Elderly patients (>65 years of age) may be more likely to experience certain adverse reactions. Use with caution.
-Common side effects of Cabazitaxel may include neutropenia, anemia, thrombocytopenia, diarrhea, nausea, vomiting, fatigue, and asthenia. Severe allergic reactions and peripheral neuropathy may also occur. -Anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, alopecia, neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia, Increased Toxicities in Elderly Patients, Hypersensitivity Reactions, Gastrointestinal Adverse Reactions, Renal Failure, Urinary Disorders Including Cystitis, Respiratory Disorders.
-Cabazitaxel may interact with drugs that are metabolized by the CYP3A4 enzyme, and caution should be exercised when co-administering with strong CYP3A4 inhibitors or inducers. -Avoid coadministration with strong CYP3A inhibitors.
